LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

LLY

1,042.37

+3.33%↑

JNJ

245.35

+1.18%↑

ABBV

228.74

+1.78%↑

NVS

165.1

+1.48%↑

MRK

122.81

+0.45%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Open

3.62 6.16

Buy Sell

Overview

Share price change

24h

Current

Min

3.41

Max

3.64

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+339.26% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-66M 188M
Previous open	-2.54
Previous close	3.62

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 lut 2026, 23:55 UTC

Market Talk

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 lut 2026, 23:53 UTC

Market Talk

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 lut 2026, 23:53 UTC

Market Talk

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 lut 2026, 23:51 UTC

Market Talk

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 lut 2026, 23:35 UTC

Market Talk

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 lut 2026, 23:21 UTC

Earnings

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 lut 2026, 23:20 UTC

Earnings

Nickel Industries 2025 Operating Profit US$126.4 Million

22 lut 2026, 23:19 UTC

Earnings

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 lut 2026, 23:19 UTC

Earnings

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 lut 2026, 23:18 UTC

Earnings

Nickel Industries Won't Pay a Final Dividend

22 lut 2026, 23:16 UTC

Earnings

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 lut 2026, 21:35 UTC

Earnings

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 lut 2026, 21:34 UTC

Earnings

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 lut 2026, 21:34 UTC

Earnings

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 lut 2026, 21:33 UTC

Earnings

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 lut 2026, 21:33 UTC

Earnings

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 lut 2026, 21:28 UTC

Earnings

Ampol Final Dividend A$0.60/Share

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Revenue A$31.37 Billion, Down 10%

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 lut 2026, 21:28 UTC

Earnings

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 lut 2026, 14:31 UTC

Acquisitions, Mergers, Takeovers

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 lut 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

20 lut 2026, 23:12 UTC

Acquisitions, Mergers, Takeovers

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 lut 2026, 22:12 UTC

Earnings

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20 lut 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20 lut 2026, 21:23 UTC

Earnings

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 lut 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 lut 2026, 21:01 UTC

Acquisitions, Mergers, Takeovers

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 lut 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

339.26% upside

12 Months Forecast

Average 15.33 USD 339.26%

High 25 USD

Low 10 USD

Based on 3 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.